Nascent Biotech to Sponsor Human Antibodies & Hybridomas Conference April 4, 2018/in Corporate News / This October 22-24, 2018, in Riga, Latvia, Human Antibodies & Hybridomas Magazine will present its annual conference. Nascent Biotech will be one of the event’s primary sponsors, with Nascent Biotech founder Dr. Mark Glassy serving as the program chairman.
Click this link to download a PDF detailing the conference details, and how to register.
Nascent Biotech is a development stage biopharmaceutical company that develops monoclonal antibodies for the treatment of various forms of cancer. The company focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company is primarily focused on developing pritumumab for the treatment of patients with brain cancer malignancies such as glioma and astrocytoma. Pritumumab is a monoclonal antibody that has been tested in Ministry of Health and Welfare approved clinical studies in 249 human brain cancer patients in the nation of Japan. The objective of the Phase I and Phase II human clinical trial was to determine the safety of pritumumab in humans and its efficacy in eliminating tumors or reducing tumor size in patients with brain cancer.
Share Structure Market Cap 13,785,699 06/07/2018 Authorized Shares 100,000,000 05/31/2018 Outstanding Shares 28,134,079 05/31/2018 Restricted 19,723,969 05/31/2018 Unrestricted 8,410,110 05/31/2018 Held at DTC 3,247,470 05/31/2018 Float 5,056,710 08/07/2017 Par Value 0.00
News 
Market Data 
Discover 
